CD22 and non-Hodgkin lymphoma: Polyimmunotargeting should contribute to increasing the efficacy of CAR T cell therapy in non-Hodgkin’s lymphomas by preventing antigen immune escape, as has been studied with dual-targeted CAR T cells for CD19-CD22 in large B cell lymphoma patients [8] and with trispecific CD19-CD20-CD22-targeted CAR T cells in preclinical models [7].